Anandamide and neutrophil function in patients with fibromyalgia

Psychoneuroendocrinology

Volumn 33, Issue 5, 2008, Pages 676-685

  Kaufmann, Ines ^a   Schelling, Gustav ^a   Eisner, Christoph ^a   Richter, Hans Peter ^a   Krauseneck, Till ^b   Vogeser, Michael ^b   Hauer, Daniela ^a   Campolongo, Patrizia ^c   Chouker, Alexander ^a   Beyer, Antje ^a   Thiel, Manfred ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anandamide; Endocannabinoid system; Fibromyalgia; Neutrophil; Pain; Stress

Indexed keywords

ANANDAMIDE; CATECHOLAMINE; HYDROCORTISONE; HYDROGEN PEROXIDE; NORADRENALIN;

ADULT; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL POPULATION; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; HEALTH STATUS; HUMAN; LEUKOCYTE; MALE; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL;

ARACHIDONIC ACIDS; CASE-CONTROL STUDIES; ENDOCANNABINOIDS; EPINEPHRINE; FEMALE; FIBROMYALGIA; HUMANS; HYDROGEN PEROXIDE; MALE; MIDDLE AGED; NEUTROPHILS; NOREPINEPHRINE; OXIDATIVE STRESS; PHAGOCYTOSIS; POLYUNSATURATED ALKAMIDES; QUESTIONNAIRES; RECEPTOR, CANNABINOID, CB2; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; ZYMOSAN;

EID: 42749086767     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.02.009     Document Type: Article

References (75)

1. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., and Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10 (2007) 870-879
2. Altindag O., and Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox. Rep. 11 (2006) 131-135
3. Arnold L.M., Hudson J.I., Keck P.E., Auchenbach M.B., Javaras K.N., and Hess E.V. Comorbidity of fibromyalgia and psychiatric disorders. J. Clin. Psychiatry 67 (2006) 1219-1225
4. Bagis S., Tamer L., Sahin G., Bilgin R., Guler H., Ercan B., and Erdogan C. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder?. Rheumatol. Int. 25 (2005) 188-190
5. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin. Exp. Rheumatol. 23 (2005) S154-S162
6. Bennett R.M., Jones J., Turk D.C., Russell I.J., and Matallana L. An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet. Disord. 8 (2007) 27 10.1186/1471-2474-8-27
7. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J. Leukoc. Biol. 78 (2005) 819-835
8. Cabral G.A., and Marciano-Cabral F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J. Neuroimmunol. 147 (2004) 127-130
9. Carrier E.J., Patel S., and Hillard C.J. Endocannabinoids in neuroimmunology and stress. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 657-665
10. Close G.L., Ashton T., McArdle A., and MacLaren D.P. The emerging role of free radicals in delayed onset muscle soreness and contraction-induced muscle injury. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 142 (2005) 257-266
11. Crofford L.J., Pillemer S.R., Kalogeras K.T., Cash J.M., Michelson D., Kling M.A., Sternberg E.M., Gold P.W., Chrousos G.P., and Wilder R.L. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37 (1994) 1583-1592
12. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., and Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 19 (2003) 5
13. Di S., Malcher-Lopes R., Cs.Halmos K., and Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 23 (2003) 4850-4857
14. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18 (2007) 129-140
15. Eisinger J., Zakarian H., Pouly E., Planatmura A., and Ayavou T. Protein peroxidation, magnesium deficiency and fibromyalgia. Magnes. Res. 9 (1996) 313-316
16. Fernandez-Rodriguez C.M., Romero J., Petros T.J., Bradshaw H., Gasalla J.M., Gutierrez M.L., Lledo J.L., Santander C., Perez-Fernandez T., Tomas E., Cacho G., and Walker J.M. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 24 (2004) 477-483
17. Fries E., Hesse J., Hellhammer J., and Hellhammer D.H. A new view on hypocortisolism. Psychoneuroendocrinology 30 (2005) 1010-1016
18. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995) 54-61
19. Gilbertson M.W., Shenton M.E., Ciszewski A., Kasai K., Lasko N.B., Orr S.P., and Pitman R.K. Smaller hippocampal volume predicts pathologicvulnerability to psychological trauma. Nat. Neurosci. 5 (2002) 1242-1247
20. Griep E.N., Boersma J.W., Lentjes E.G., Prins A.P., van der Korst J.K., and de Kloet E.R. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J. Rheumatol. 25 (1998) 1374-1381
21. Gur A., Cevik R., Sarac A.J., Colpan L., and Em S. Hypothalamic-pituitary-gonadal axis and cortisol in young women with primary fibromyalgia: the potential roles of depression, fatigue, and sleep disturbance in the occurrence of hypocortisolism. Ann. Rheum. Dis. 63 (2004) 1504-1506
22. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal J.D., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
23. Hudson J.I., Arnold L.M., Keck P.E., Auchenbach M.B., and Pope H.G. Family study of fibromyalgia and affective spectrum disorder. Biol. Psychiatry 56 (2004) 884-891
24. Jaeger K., Scheinichen D., Heine J., Andre M., Bund M., Piepenbrock S., and Leuwer M. Remifentanil, fentanyl, and alfentanil have no influence on the respiratory burst of human neutrophils in vitro. Acta Anaesthesiol. Scand. 42 (1998) 1110-1113
25. Karl A., Schaefer M., Malta L.S., Dorfel D., Rohleder N., and Werner A. A meta-analysis of structural brain abnormalities in PTSD. Neurosci. Biobehav. Rev. 30 (2006) 1004-1031
26. Kaufmann I., Hoelzl A., Schliephake F., Hummel T., Chouker A., Peter K., and Thiel M. Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity. Shock 26 (2006) 254-261
27. Kaufmann I., Eisner C., Richter P., Huge V., Beyer A., Chouker A., Schelling G., and Thiel M. Psychoneuroendocrine stress response may impair neutrophil function in complex regional pain syndrome. Clin. Immunol. 125 (2007) 103-111
28. Kaufmann I., Hoelzl A., Schliephake F., Hummel T., Chouker A., Lysenko L., Peter K., and Thiel M. Effects of adenosine on functions of polymorphonuclear leukocytes from patients with septic shock. Shock 27 (2007) 25-31
29. Keh D., Boehnke T., Weber-Cartens S., Schulz C., Ahlers O., Bercker S., Volk H.D., Doecke W.D., Falke K.J., and Gerlach H. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock-a double-blind, randomized, placebo-controlled, crossover study. Am. J. Resp. Crit. Care Med. 167 (2003) 512-520
30. Kivimäki M., Leino-Arjas P., Virtanen M., Elovainio M., Keltikangas-Jarvinen L., Puttonen S., Vartia M., Brunner E., and Vahtera J. Work stress and incidence of newly diagnosed fibromyalgia: prospective cohort study. J. Psychosom. Res. 57 (2004) 417-422
31. 2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. J. Pharmacol. Exp. Ther. 315 (2005) 641-647
32. Krumholz W., Demel C., Jung S., Meuthen G., and Hempelmann G. The influence of fentanyl and alfentanil on functions of human polymorphonuclear leukocytes in vitro. Acta Anaesthesiol. Scand. 37 (1993) 386-389
33. Krumholz W., Endrass J., Knecht J., and Hempelmann G. The effects of midazolam, droperidol, fentanyl, and alfentanil on phagocytosis and killing of bacteria by polymorphonuclear leukocytes in vitro. Acta Anaesthesiol. Scand. 39 (1995) 624-627
34. Kwiatek R., Barnden L., Tedman R., Jarrett R., Chew J., Rowe C., and Pile K. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence reduction in the pontine tegmentum and thalami. Arthritis Rheum. 43 (2000) 2823-2833
35. Kyrou I., and Tsigos C. Stress mechanisms and metabolic complications. Horm. Metab. Res. 39 (2007) 430-438
36. Ligresti A., Cascio M.G., and Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 615-623
37. Loevinger B.L., Müller D., Alonso C., and Coe C.L. Metabolic syndrome in women with chronic pain. Metabolism 56 (2007) 87-93
38. Macedo J.A., Hesse J., Turner J.D., Ammerlaan W., Gierens A., Hellhammer D.H., and Müller C.P. Adhesion molecules and cytokine expression in fibromyalgia patients: increased L-selectin on monocytes and neutrophils. J. Neuroimmunol. 188 (2007) 159-166
39. Maes M., Mihaylova I., and Leunis J.C. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro. Endocrinol. Lett. 27 (2006) 615-621
40. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di Marzo V., and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
41. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
42. McBeth J., Chiu Y.H., Silman A.J., Ray D., Morriss R., Dickens C., Gupta A., and MacFarlane G.J. Hypothalamic-pituitary-adrenal stress axis function and the relationship with chronic widespread pain and its antecedents. Arthritis Res. Ther. 7 (2005) R992-R1000
43. Mikawa K., Akamatsu H., Nishina K., Uesugi T., and Niwa Y. The effects of pentazocine, buprenorphine and butorphanol on human neutrophil functions. Acta Anaesthesiol. Scand. 50 (2006) 643-644
44. Monteleone P., Matias I., Martiadis V., De Petrocellis L., Maj M., and Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30 (2005) 1216-1221
45. Mountz J.M., Bradley L.A., Modell J.G., Alexander R.W., Triana-Alexander M., Aaron L.A., Stewart K.E., Alarcon G.S., and Mountz J.D. Fibromyalgia in women. Abnormalities in regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 38 (1995) 926-938
46. Offenbaecher M., Waltz M., and Schoeps P. Validation of a German version of the Fibromyalgia Impact Questionnaire (FIQ-G). J. Rheumatol. 27 (2000) 1984-1988
47. Patel S., Wohlfeil E.R., Rademacher D.J., Carrier E.J., Perry L.J., Kundu A., Falck J.R., Nithipatikom K., Campbell W.B., and Hillard C.J. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br. J. Pharmacol. 139 (2003) 1005-1013
48. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
49. Rauch S.L., Shin L.M., and Phelps E.A. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research-past, present, and future. Biol. Psychiatry 60 (2006) 376-382
50. Robinson R.L., Birnbaum H.G., Morley M.A., Sisitsky T., Greenberg P.E., and Claxton A.J. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J. Rheumatol. 30 (2003) 1318-1325
51. Roy-Byrne P., Smith W.R., Goldberg J., Afari N., and Buchwald D. Post-traumatic stress disorder among patients with chronic pain and chronic fatigue. Psychol. Med. 34 (2004) 363-368
52. 2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142 (1997) 278-287
53. Schelling G., Hauer D., Azad S.C., Schmoelz M., Chouker A., Schmidt M., Hornuss C., Rippberger M., Briegel J., Thiel M., and Vogeser M. Effects of general anesthesia on anandamide blood levels in humans. Anesthesiology 104 (2006) 273-277
54. Schelling, G., Lutz, J., Krauseneck, T., Roozendaal, B., Jaeger, L., 2006b. Diffusion-tensor imaging of brain structures regulating emotional memory in humans with chronic stress-related disorders. Neurosci. Meeting Planner, Online Program# 311.9.
55. Schmidt-Wilcke T., Luerding R., Weigand T., Jürgens T., Schuirer G., and Leinisch E. Striatal grey matter increase in patients suffering from fibromyalgia-a voxel-based morphometry study. Pain 132 Suppl. 1 (2007) S109-S116
56. Stoll C., Kapfhammer H.P., Rothenhausler H.B., Haller M., Briegel J., Schmidt M., Krauseneck T., Durst K., and Schelling G. Sensitivity and specificity of a screening test to document traumatic experiences and to diagnose post-traumatic stress disorder in ARDS patients after intensive care treatment. Intensive Care Med 25 (1999) 697-704
57. Suplita R.L., Farthing J.N., Gutierrez T., and Hohmann A.G. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 49 (2005) 1201-1209
58. Tasker J. Endogenous cannabinoids take the edge off neuroendocrine responses to stress. Endocrinology 145 (2004) 5429-5430
59. Thieme K., Turk D.C., and Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom. Med. 66 (2004) 837-844
60. Torpy D.J., Papanicolaou D.A., Lotsikas A.J., Wilder R.L., Chrousos G.P., and Pillemer S.R. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6. A pilot study in fibromyalgia. Arthritis Rheum. 43 (2000) 872-880
61. Trush M.A., Reasor M.J., Wilson M.E., and Van Dyke K. Comparison of the interaction of tricyclic antidepressants with human polymorphonuclear leukocytes as monitored by the generation of chemiluminescence. Chem. Biol. Interact. 28 (1979) 71-81
62. Tsigos C., and Chrousos G.P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53 (2002) 865-871
63. Ullrich O., Merker K., Timm J., and Tauber S. Immune control by endocannabinoids-new mechanisms of neuroprotection?. J. Neuroimmunol. 184 (2007) 127-135
64. 2+ influx via TRPV1 channels. EMBO J. 24 (2005) 3026-3037
65. Van Houdenhove B., and Luyten P. Stress, depression and fibromyalgia. Acta Neurol. Belg. 106 (2006) 149-156
66. Van Houdenhove B., Egle U., and Luyten P. The role of life stress in fibromyalgia. Curr. Rheumatol. Rep. 7 (2005) 365-370
67. Vogeser M., and Schelling G. Pitfalls in measuring the endocannabinoid 2-arachidonoyl glcyerol in biological samples. Clin. Chem. Lab. Med. 45 (2007) 1023-1025
68. Vogeser M., Hauer D., Christina A.S., Huber E., Storr M., and Schelling G. Release of anandamide from blood cells. Clin. Chem. Lab. Med. 44 (2006) 488-491
69. Weir P.T., Harlan G.A., Nkoy F.L., Jones S.S., Hegmann T., and Lyon J.L. The incidence of fibromyalgia and its associated comorbidities-a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. J. Clin. Rheumatol. 12 (2006) 124-128
70. Weisaeth L. Torture of a Norwegian ship's crew. The torture, stress reactions and psychiatric after-effects. Acta Psychiatr. Scand. Suppl. 355 (1989) 63-72
71. Weissbecker I., Floyd A., Dedert E., Salmon P., and Sephton S. Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology 31 (2006) 312-324
72. Wingenfeld K., Wagner D., Schmidt I., Meinlschmidt G., Hellhammer D.H., and Heim C. The low-dose dexamethasone suppression test in fibromyalgia. J. Psychosom. Res. 62 (2007) 85-91
73. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., Fam A.G., Farber S.J., Fiechtner J.J., Franklin C.M., Gatter R.A., Hamaty D., Lessard J., Lichtbroun A.S., Masi A.T., McCain G.A., Reynolds W.J., Romano T.J., Russell I.J., and Sheon R.P. The American-College-of-Rheumatology 1990 criteria for the classification of fibromyalgia-report of the multicenter criteria committee. Arthritis Rheum. 33 (1990) 160-172
74. 1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96 (1999) 5780-5785
75. Ziring D., Wei B., Velazquez P., Schrage M., Buckley N.E., and Braun J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58 (2006) 714-725